<DOC>
	<DOCNO>NCT00872326</DOCNO>
	<brief_summary>The aim study assess efficacy safety autologous transplantation bone-marrow cell therapeutic angiogenesis vasculogenesis diabetic patient non-revascularizable critical limb ischemia .</brief_summary>
	<brief_title>Autologous Bone Marrow Derived Mononuclear Cells Treating Diabetic Patients With Critical Limb Ischemia</brief_title>
	<detailed_description>Phase I/II , prospective , single-center study , consecutive inclusion 20 diabetic patient critical limb ischemia due bellow-the-knee extensive arterial disease . After inclusion , patient submit bone-marrow aspiration ( 30 ml ) sedation . Autologous bone-marrow mononuclear cell ( minimum 80 million mononuclear cell ) infuse intraarterially popliteal artery block antegrade perfusion 3 minute . Clinical angiographic follow-up perform 3 month infusion ass efficacy autologous mononuclear cell transplantation term : - Changes below-the-knee angiography baseline 3 month follow-up . - Changes Ankle-Brachial pressure Index , transcutaneous oxygen pressure , size main ischemic ulcer also assess target limb .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Diabetic patient treatment ( type I II ) Critical limb ischemia ( rest pain and/or nonhealing ischemic ulcer last 4 week , and/or AnkleBrachial Index &lt; 0,8 ) Not suitable revascularized ( surgical interventional consensus ) Neoplastic disease and/or hematologic disease last 2 year Diabetic retinopathy Ischemic ulcer great 10 cm2 Major amputation target limb Life expectancy &gt; 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Diabetes Complications</keyword>
	<keyword>Lower limb ischemia</keyword>
	<keyword>Adult stem cell</keyword>
</DOC>